Recurrence-Free Survival as a Surrogate for Overall Survival Among Patients with Intrahepatic Cholangiocarcinoma Following Upfront Surgery: An International Multi-institutional Analysis
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Recurrence-free survival (RFS) correlates moderately with overall survival (OS) after intrahepatic cholangiocarcinoma (ICC) surgery. Three-year RFS may reliably predict five-year OS in ICC patients, aiding future clinical trial design.
Area Of Science
- Hepatobiliary surgery
- Surgical oncology
- Clinical trial design
Background
- The utility of recurrence-free survival (RFS) as a surrogate for overall survival (OS) in intrahepatic cholangiocarcinoma (ICC) post-surgery is undefined.
- This study evaluates the RFS-OS correlation in ICC patients undergoing upfront surgical resection.
Purpose Of The Study
- To determine if RFS is a reliable surrogate endpoint for OS in ICC patients after surgical resection.
- To assess the correlation between RFS and OS in ICC.
Main Methods
- Analysis of 1541 patients who underwent curative-intent ICC surgery (2000-2023) from an international database.
- Rank correlation assessed RFS and OS relationship.
- Landmark analysis evaluated concordance between 5-year OS and recurrence status at various postoperative time points.
Main Results
- A moderately strong correlation (ρ = 0.79) was found between RFS and OS.
- Landmark analysis showed increasing concordance between 5-year OS and recurrence status over time, plateauing at 3 years.
- Median RFS was 22.6 months and median OS was 41.5 months.
Conclusions
- RFS and OS show a moderately strong correlation in patients with ICC undergoing curative resection.
- Three-year RFS is a potential surrogate endpoint for predicting 5-year OS in ICC.
- RFS should be considered in future ICC clinical trial designs.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...